https://www.selleckchem.com/pr....oducts/tiragolumab-a
5; 95% CI, 4.9-18.1; p 0.01) and all untreated patients (ATE, 7.43; 95% CI, 4.7-10.2; p 0.01). Moreover, patients with RRT had significantly worse functional and mortality outcomes. SLED treatment in ICH patients with CKD was associated with significant increase in rate and frequency of PHE expansion. Absolute increase in PHE during 48-h post-ICH was associated with increased mortality and worse functional outcomes. Further prospective and multicenter evaluation is needed to differentiate the effects of RRT on h
Like
Comment
Share
